Objective The aim of this review is to provide a summary of the literature on risk-sharing
agreements, including conceptual, theoretical and empirical (number of agreements and …

This study reviews and evaluates the national drug formulary system used to improve patient
access to new drugs by making reimbursement decisions for new drugs as part of the South …

Em abril de 2019, foi assinada a portaria de incorporação do medicamento nusinersena no
Sistema Único de Saúde (SUS). É o medicamento mais caro já incorporado ao SUS, para …

BACKGROUND AND OBJECTIVE: To facilitate affordable and equitable access to essential
and cost-effective medicines for patients, governments can use a mix of policy measures …

Objectives The aim of this review is to assess the current state of empirical research
regarding the effectiveness of national pricing regulations of the patent-protected market for …

Background: Cell and gene therapies are associated with uncertainty around their value
claims at launch due to limitations of supporting clinical data; furthermore, their high costs …

Significant progress has been made in our understanding of the molecular lesions
responsible for tumor cells to exhibit uncontrolled growth while circumventing normal …

Managed entry agreements (MEAs)—a type of formal institutional arrangement between
pharmaceutical companies and payers for sharing the risk with respect to the introduction of …

Background: Traditional drug payment schemes in Catalonia are generally based on the
negotiation of fixed prices; however, disadvantages arise in the case of innovative therapies …

Introduction: There is significant difference in utilization of patented medicines in the EU, as
pharmaceuticals at Western European price levels are usually not cost-effective in Central …